Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type 2 Diabetes
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the study is to compare, in a population of patients with type 2 diabetes, open-loop insulin pump treatment with the CamAPS HX (Camdiab) Fully Closed Loop Automated Insulin Therapy system, on the efficacy and safety of use of the Fully Closed Loop, as well as on psycho-social criteria of device acceptability, quality of life and diabetes burden. This is an open, multi-center, randomized, cross-over study, based on several observational or controlled trials carried out in Cambridge by Prof. Hovorka's team (see paragraph 4 below). The study will comprise a run-in phase followed by a 1st sequence in which randomized patients will use the Ypsomed pump (Ypsomed) and the FreeStyle Libre 3 sensor in open loop for 12 weeks Versus the Ypsomed pump (Ypsomed) coupled with the CamAPS HX algorithm and the FreeStyle Libre 3 sensor in full closed loop. At the end of this 1ère sequence, all patients will undergo a 2-4 week washout, during which they will use the Ypsomed pump and the FreeStyle Libre 3 sensor in open loop, and then in the 2nd sequence of the study, patients will switch to the other treatment for a further 12 weeks. A total of 80 patients on insulin pumps for at least 6 months will be recruited from 9 French centers. All patients will receive training in the use of the Ypsomed pump, the FreeStyle Libre 3 sensor and the CamAPS HX algorithm. The primary objective is Time on Target 70-180 mg/dl of 24h measured during the 12 weeks of each therapeutic period. Secondary objectives will be Time in Target 70-180 mg/dl day and night, Time above Target \> 180 mg/dl and \> 250 mg/dl, Time below Target \< 70 mg/dl and \< 54 mg/dl, time in the narrow target range 70-140 mg/dL, mean 24h blood glucose and glycemic variability measured over the 12 weeks of each treatment sequence, HbA1c, weight, total insulin dose and psychosocial endpoints assessed at the start and end of each treatment sequence. Safety data studied will include diabetes-related adverse events (ketoacidosis, symptomatic and severe hypoglycemia) and medical device-related adverse events (pump and sensor).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Closed loop — Ypsomed pump (Ypsomed), CamAPS HX application activated, Android smartphone. Freestyle 3 sensors (Abbott)
  • Device: Open loop — Ypsomed pump (Ypsomed). Android smartphone. Freestyle 3 sensors (Abbott)

Primary Outcomes

  • Time on target [70-180] mg/dl over 24h for the 12 weeks of each treatment sequence (from baseline for the 12 weeks of each treatment sequence)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-05
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Caen
Collaborators: Abbott, mylife Diabetes Care AG
Contact Information
Study Contact:
Yves REZNIK, MD PhD
0231065781
drci-secretariat@chu-caen.fr
Caen University Hospital
Interventions
  • Device: Closed loop — Ypsomed pump (Ypsomed), CamAPS HX application activated, Android smartphone. Freestyle 3 sensors (Abbott)
  • Device: Open loop — Ypsomed pump (Ypsomed). Android smartphone. Freestyle 3 sensors (Abbott)
Study Locations (1 sites)
Caen University Hospital, Caen, France
Eligibility Criteria
Inclusion Criteria: * Age \> 18 * Type 2 diabetes for at least 12 months * On insulin pump for at least 6 months, without/with adjuvant treatment exclusively with GLP1-Ra, iSGLT2, metformin for at least 3 months * Autonomy in the management of the pump and the glucose sensor * HbA1c ≥ 7.5% and \< 12 * Participant's agreement to wear and use the Ypsomed with the CamAPS HX algorithm and Free Style Libre 3 sensor, and to honor the study visit schedule * For women of childbearing age, effective contraception is required (estrogen-progestin pill, IUD, implant). Exclusion Criteria: * Type 1 diabetes or monogenic diabetes * Use of U500 or U200 insulin concentrate in the pump in the last 3 months * Allergy to insulin or to the adhesives used * Severe insulin resistance defined by a daily insulin requirement of more than 1.5 U/kg * History of severe hypoglycemia \> 1 time in the last 6 months. * Current or planned use of steroids (oral, injectable) or any treatment likely to have an impact on blood glucose levels within the last 30 days. * Current or planned pregnancy, breastfeeding * Severe renal failure defined as GFR \< 30 ml/mn * Proliferative retinopathy or severe maculopathy with risk of worsening during the study * Vision or hearing problems that could compromise safe use of the device * Acute vascular event within the last 3 months * No autonomy for pump treatment * Alcohol or substance abuse * Legal protection (guardianship, curatorship) * Any somatic or psychological condition compromising participation in the study * Participation in another clinical trial
Conditions Standard Quadruple Antiemetic Therapy, E...
Phase PHASE3
Enrollment 388
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to elucidate the therapeutic efficacy of electroacupuncture in managing chemotherapy-induced gastrointestinal symptom clusters through clinical research. Building upon this foundation, multi-omics analyses will be conducted to investigate the regulatory effects and underlying mechanisms of electroacupuncture on gastrointestinal symptoms. Ultimately, genomic studies will be performed to further clarify the key targets of electroacupuncture intervention, thereby providing high-level evidence-based medical support and theoretical foundations for optimizing electroacupuncture strategies in addressing chemotherapy-induced gastrointestinal symptoms in patients with cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Device: electroacupuncture — The acupuncturist applied needles at four acupoints: Zusanli (ST36), Neiguan (PC6), Hegu (LI4), and Zhaohai (KI6), with insertion depths of approximately 20 mm, 15 mm, 20 mm, and 5 mm respectively. Electrical stimulation was delivered in continuous wave mode at 2 Hz frequency with current intensity ≤10 mA (adjusted according to patient tolerance), administered for 30 minutes per session.
  • Drug: standard quadruple antiemetic therapy — Olanzapine (2.5 mg orally daily, days 1-4), dexamethasone (10 mg intravenously day 1; 7.5 mg intravenously days 2-3), a 5-HT₃ antagonist (palonosetron 0.25 mg intravenously or 0.5 mg orally, or ondansetron 8 mg intravenously or 8 mg orally twice, or tropisetron 5 mg intravenously, all on day 1), and an NK₁ antagonist (fosaprepitant 150 mg intravenously, or aprepitant 130 mg intravenously, or oral aprepitant 125 mg day 1 then 80 mg days 2-3, or netupitant 300 mg orally day 1).
  • Device: sham electroacupuncture — The same acupoints as the electroacupuncture group were referenced, but with sham acupuncture (minimal insertion at non-acupoint locations) and sham electrical stimulation, while maintaining the same treatment duration and course as the electroacupuncture group.
  • Drug: standard quadruple antiemetic therapy — Olanzapine (2.5 mg orally daily, days 1-4), dexamethasone (10 mg intravenously day 1; 7.5 mg intravenously days 2-3), a 5-HT₃ antagonist (palonosetron 0.25 mg intravenously or 0.5 mg orally, or ondansetron 8 mg intravenously or 8 mg orally twice, or tropisetron 5 mg intravenously, all on day 1), and an NK₁ antagonist (fosaprepitant 150 mg intravenously, or aprepitant 130 mg intravenously, or oral aprepitant 125 mg day 1 then 80 mg days 2-3, or netupitant 300 mg orally day 1). All the antiemetic drugs used are the same as those in the true acupuncture group.

Primary Outcomes

  • The incidence of chemotherapy-induced gastrointestinal symptom clusters, including nausea, vomiting, poor appetite, and xerostomia, within 120 hours after chemotherapy. (120 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-08-21
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 388 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiuda Zhao
Contact Information
Study Contact:
Jiuda Zhao,Dr
869716230893
jiudazhao@126.com
Qinghai University Affiliated Hospital
Interventions
  • Device: electroacupuncture — The acupuncturist applied needles at four acupoints: Zusanli (ST36), Neiguan (PC6), Hegu (LI4), and Zhaohai (KI6), with insertion depths of approximately 20 mm, 15 mm, 20 mm, and 5 mm respectively. Electrical stimulation was delivered in continuous wave mode at 2 Hz frequency with current intensity ≤10 mA (adjusted according to patient tolerance), administered for 30 minutes per session.
  • Drug: standard quadruple antiemetic therapy — Olanzapine (2.5 mg orally daily, days 1-4), dexamethasone (10 mg intravenously day 1; 7.5 mg intravenously days 2-3), a 5-HT₃ antagonist (palonosetron 0.25 mg intravenously or 0.5 mg orally, or ondansetron 8 mg intravenously or 8 mg orally twice, or tropisetron 5 mg intravenously, all on day 1), and an NK₁ antagonist (fosaprepitant 150 mg intravenously, or aprepitant 130 mg intravenously, or oral aprepitant 125 mg day 1 then 80 mg days 2-3, or netupitant 300 mg orally day 1).
  • Device: sham electroacupuncture — The same acupoints as the electroacupuncture group were referenced, but with sham acupuncture (minimal insertion at non-acupoint locations) and sham electrical stimulation, while maintaining the same treatment duration and course as the electroacupuncture group.
  • Drug: standard quadruple antiemetic therapy — Olanzapine (2.5 mg orally daily, days 1-4), dexamethasone (10 mg intravenously day 1; 7.5 mg intravenously days 2-3), a 5-HT₃ antagonist (palonosetron 0.25 mg intravenously or 0.5 mg orally, or ondansetron 8 mg intravenously or 8 mg orally twice, or tropisetron 5 mg intravenously, all on day 1), and an NK₁ antagonist (fosaprepitant 150 mg intravenously, or aprepitant 130 mg intravenously, or oral aprepitant 125 mg day 1 then 80 mg days 2-3, or netupitant 300 mg orally day 1). All the antiemetic drugs used are the same as those in the true acupuncture group.
Study Locations (1 sites)
Qinghai University Affiliated Hospital, Xining, Qinghai 810000 China
Eligibility Criteria
Inclusion Criteria: 1. Radiologically and pathologically confirmed stage I-III breast cancer; 2. An Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1; 3. Age between 18 and 75 years; 4. Scheduled to receive highly emetogenic chemotherapy regimens, such as EC (epirubicin + cyclophosphamide) or platinum-based regimens, during the first cycle of neoadjuvant/adjuvant chemotherapy; 5. No prior acupuncture treatment within one month before enrollment; 6. Voluntary participation in the study with written informed consent obtained; (7) An expected survival of at least 3 months; (8) Premenopausal women must agree to use contraception during the study period; (9) Adequate bone marrow, liver, and kidney function as defined by standard laboratory criteria. Exclusion Criteria: 1. Patients with advanced-stage cancer; 2. Those undergoing concurrent chemoradiotherapy; 3. Individuals with severe impairment of vital organ function who cannot tolerate standard-dose chemotherapy; 4. Patients with contraindications to acupuncture, such as active skin infections; 5. Those with digestive system diseases accompanied by nausea and vomiting symptoms that may interfere with accurate assessment; 6. Patients with a history of xerostomia; 7. Individuals with known allergies to the study drugs; 8. Pregnant or breastfeeding patients; 9. Individuals currently using medications with antiemetic activity, such as 5-HT3 receptor antagonists, corticosteroids (except at physiological doses), dopamine receptor antagonists, minor tranquilizers, antihistamines, and benzodiazepines (except for nighttime sedation); 10. Patients with seizure disorders requiring anticonvulsant therapy; 11. Those receiving thiazides as chronic antipsychotic medications; 12. Those with known arrhythmias, uncontrolled congestive heart failure, or acute myocardial infarction.
Conditions Inoperable Locally Advanced HER2-Negativ...
Phase PHASE1, PHASE2
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the safety and effectiveness of JSKN016 in combination with different treatments for patients with HER2-negative breast cancer that cannot be removed by surgery or has spread to other parts of the body. The study includes four groups of patients based on treatment history and tumor characteristics. Each group will receive JSKN016 with chemotherapy or immunotherapy. The goal is to find out how well the treatment works and how safe it is.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: JSKN016 — JSKN016 is administered via intravenous infusion at doses of 5mg/kg or 6mg/kg every 3 weeks, starting on Day 1 of each cycle. If the 5mg/kg dose is well tolerated during the safety lead-in phase, the dose may be increased to 6mg/kg for subsequent cycles.
  • Drug: Capecitabine — The drug is administered orally at a dose of 1000mg/m², twice daily for two weeks, followed by a one-week break. Treatment cycles repeat every three weeks.
  • Drug: Paclitaxel (albumin bound) — The drug is administered intravenously at a dose of 125mg/m², with infusions on Day 1 and Day 8 of each treatment cycle. The treatment cycle is repeated every 3 weeks.
  • Drug: Eribulin — The drug is administered intravenously at a dose of 1.4mg/m², with infusions on Day 1 and Day 8 of each treatment cycle. The treatment cycle is repeated every 3 weeks.
  • Drug: Pembrolizumab — The drug is administered intravenously at a fixed dose of 200mg, with infusions on Day 1 of each 3-week treatment cycle.

Primary Outcomes

  • Objetctive Response Rate (ORR) (From baseline until disease progression, death, or end of treatment, whichever occurs first (up to approximately 24 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-06-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Contact Information
Study Contact:
Jian Zhang
+86-21-64175590
syner2000@126.com
Jian Zhang
+86 18017312990
Fudan University Shanghai Cancer center
Interventions
  • Drug: JSKN016 — JSKN016 is administered via intravenous infusion at doses of 5mg/kg or 6mg/kg every 3 weeks, starting on Day 1 of each cycle. If the 5mg/kg dose is well tolerated during the safety lead-in phase, the dose may be increased to 6mg/kg for subsequent cycles.
  • Drug: Capecitabine — The drug is administered orally at a dose of 1000mg/m², twice daily for two weeks, followed by a one-week break. Treatment cycles repeat every three weeks.
  • Drug: Paclitaxel (albumin bound) — The drug is administered intravenously at a dose of 125mg/m², with infusions on Day 1 and Day 8 of each treatment cycle. The treatment cycle is repeated every 3 weeks.
  • Drug: Eribulin — The drug is administered intravenously at a dose of 1.4mg/m², with infusions on Day 1 and Day 8 of each treatment cycle. The treatment cycle is repeated every 3 weeks.
  • Drug: Pembrolizumab — The drug is administered intravenously at a fixed dose of 200mg, with infusions on Day 1 of each 3-week treatment cycle.
Study Locations (1 sites)
Fudan University Shanghai Cancer center, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. Capable of understanding and signing the informed consent form. 2. Aged ≥18 and ≤75 years, regardless of sex. 3. Histologically or cytologically confirmed inoperable locally advanced or metastatic HER2-negative breast cancer. 4. Hormone receptor-positive participants with progression/intolerance after standard endocrine therapy, or unsuitable for it. 5. Disease progression confirmed by radiological evidence post-systemic treatment. 6. Available archived or newly obtained tumor tissue/biopsy. 7. No prior systemic therapy for advanced disease, except for prior endocrine ± targeted therapy or CDK4/6 inhibitors. 8. Measurable non-CNS lesion per RECIST 1.1. 9. Expected survival ≥3 months. 10. ECOG performance status of 0 or 1. 11. Contraceptive use agreement for fertile participants. 12. Adequate organ function within 7 days of enrollment: * Bone marrow: ANC ≥1.5 × 10⁹/L, Hemoglobin ≥90 g/L, Platelets ≥100 × 10⁹/L. * Liver: Bilirubin ≤1.5 × ULN, ALT/AST ≤3 × ULN. * Renal: Creatinine ≤1.5 × ULN or Ccr ≥60 mL/min. * Coagulation: INR/PT ≤1.5 × ULN, APTT ≤1.5 × ULN. 13. LVEF ≥50%. Exclusion Criteria: 1. CNS metastasis (except stable cases treated with radiation or surgery). 2. Unstable spinal cord compression or untreated history. 3. Recent live vaccine (except seasonal flu vaccines). 4. Recent anti-tumor treatment within 28 days or 5 half-lives (whichever is shorter). 5. Recent palliative therapy within 14 days. 6. Major surgery within 28 days or planned during the study. 7. Severe gastrointestinal issues or recent major GI bleeding. 8. Uncontrolled pleural/peritoneal effusions or cachexia. 9. Prior HER3/TROP2-targeted therapy or topoisomerase I inhibitors. 10. Other malignancies within 5 years (except certain skin or localized cancers). 11. Current interstitial lung disease or uncontrolled infections. 12. Severe hypercalcemia or uncontrolled cancer-related pain. 13. Autoimmune diseases, unless stable with treatment. 14. Uncontrolled comorbidities (e.g., active infections, cardiovascular issues). 15. Toxicities from previous treatments not resolved to CTCAE ≤1. 16. Recent steroid use or need for systemic immunosuppressive therapy. 17. Allergy to study drug components. 18. Pregnancy or breastfeeding.
Conditions Obesity and Diabetes Mellitus, Type 2, D...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Hispanic adolescents in the U.S. are disproportionately burdened by type 2 diabetes (T2D) compared to non-Hispanic white youth (0.079% vs. 0.017%) contributing to higher rates of T2D-related vascular complications, cardiovascular disease, and mortality, among this population. Disparities in T2D are driven in part by independent, modifiable risk factors including low levels of physical activity, sleep, and poor diet. Lifestyle interventions are the cornerstone for maintaining glucose control and managing T2D. However, few studies have developed and tested lifestyle interventions for Hispanic youth with T2D. Digital health interventions that promote healthy lifestyle behaviors like physical activity, sleep, and diet, have demonstrated effectiveness among adults. Studies that use health-based smartphone applications have demonstrated preliminary efficacy for improving health-related lifestyle behaviors as these digital tools leverage behavior change techniques (e.g. self-monitoring, goal-setting, feedback) that have proven effective. Use of digital technology allows for the continuous delivery of intervention content into the home environment extending the reach of clinical care while engaging youth in a format that is age-appropriate given that today's youth are digital frontrunners. Unfortunately, while the use of digital health interventions have increased, few studies have focused on adolescents with overweight and obesity who are at high risk for T2D. The purpose of this study is to 1) develop a mobile health platform for remote and continuous monitoring of activity, sleep, and nutrition and 2) conduct a pilot study (30 days) to evaluate the efficacy of a novel digital health platform in improving obesity-related health outcomes outcomes in Hispanic adolescents (12-18 years; N=30) population.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: PATHS-UP Mobile Phone Application — Youth in the intervention will be given access to a health-based mobile phone application and a remote bluetooth scale. The app is focused on promoting health education and self-monitoring. For 30 days youth will be asked to engage with content focused on promoting healthy sleep, physical activity, and dietary habits every day. Youth will also be asked to self-monitor health behaviors using the app as it pulls in data on daily steps from the accelerometer embedded within the smartphone, information on weight from daily weigh-ins using the remote scale, sleep via a weekly survey within the app, and caloric intake using a daily food log that is powered through artificial intelligence within the app.

Primary Outcomes

  • Rate of Recruitment (From enrollment to the end of the 30 day study.)
  • Feasibility of Technology (through study completion, an average of 30 days)
  • Usability (At the end of the 30 day study.)
  • Acceptability (At the end of the 30 day study.)
  • Acceptability (at the end of the 30 day study)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-30
Completion: 2026-08-01
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Baylor College of Medicine
Collaborators: U.S. National Science Foundation
Contact Information
Study Contact:
Pedro Garcia
(732)798-7092
Pedro.Garcia@bcm.edu
Erica Soltero Principal Investigator
402-910-0832
soltero@bcm.edu
Children's Nutrition Research Center
Interventions
  • Behavioral: PATHS-UP Mobile Phone Application — Youth in the intervention will be given access to a health-based mobile phone application and a remote bluetooth scale. The app is focused on promoting health education and self-monitoring. For 30 days youth will be asked to engage with content focused on promoting healthy sleep, physical activity, and dietary habits every day. Youth will also be asked to self-monitor health behaviors using the app as it pulls in data on daily steps from the accelerometer embedded within the smartphone, information on weight from daily weigh-ins using the remote scale, sleep via a weekly survey within the app, and caloric intake using a daily food log that is powered through artificial intelligence within the app.
Study Locations (1 sites)
Children's Nutrition Research Center, Houston, Texas 77003 United States
Eligibility Criteria
Inclusion Criteria: * self-identify as Hispanic or Latino * 12-18 years * BMI% in the 85th-95th range, * Owns their own iphone Exclusion Criteria: * Currently enrolled in a health program * Diagnosed with T2D * Present with a disease or condition that would prevent one from engaging in activity
Conditions Breast Cancer
Phase PHASE2
Enrollment 411
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Early triple negative breast cancer patients who do not achieve pathologic complete response after neoadjuvant chemotherapy with or without immunotherapy have bad prognosis. ctDNA effectively identified patients with highest relapse risk. This trial aims to explore whether the combination of anlotinib, immunotherapy and capecitabine could improve the outcome of this subgroup of high relapse risk patients compared with investigator's choice of therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Anlotinib , — Anlotinib 8mg qd PO,357days
  • Drug: Benmelstobart — Benmelstobart 200mg i.v. Q3W
  • Drug: Capecitabine — Capecitabine 1000 or 1250 mg/m2 BID day1-14

Primary Outcomes

  • iDFS (from randomization to any of the following events: local or distant relapse; contralateral breast caner, death of any cause,assessed up to 36 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-04-10
Completion: 2036-01-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 411 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Shunying Li, PHD
020-34071156
lishunying@foxmail.com
Sun Yat-sen Memorial Hospital
Ziqing Feng, Bachelor
+86-13060764510
Sun Yat-sen Memorial Hospital
Interventions
  • Drug: Anlotinib , — Anlotinib 8mg qd PO,357days
  • Drug: Benmelstobart — Benmelstobart 200mg i.v. Q3W
  • Drug: Capecitabine — Capecitabine 1000 or 1250 mg/m2 BID day1-14
Study Locations (1 sites)
Sun Yat-sen Memorial Hospital, Guangzhou, Guangodng China
Eligibility Criteria
Inclusion Criteria: * Stage II-III breast cancer patients, excluding occult breast cancer, inflammatory breast cancer, metaplasia breast cancer * TNBC patients. TNBC was defined as ER \<= 10%, PR \<=10%, HER 0-1, or HER2 2+ and FISH negative. Exclusion Criteria: \-
Conditions Breast Cancer
Phase Not Applicable
Enrollment 2766
Locations 42 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This prospective, observational, multicenter study aims at evaluating the efficacy of adjuvant ribociclib in combination with hormone therapy (aromatase inhibitor ± GnRH aginost) in various subgroups of patients with HR+HER2- stage II-III breast cancer in real clinical practice in Russia. Subgroup division will be based on the tumor grade, lymph node involvement, and the response to test hormone therapy. The study will consist of two cohorts: a prospective one with patients receiving adjuvant therapy with ribociclib combined with Aromatase inhibitors (AI), and a retrospective one with patients receiving adjuvant therapy with AI alone. Thus, both primary data collection and secondary use of data will be organized.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Ribociclib — CDK4/6 inhibitor
  • Drug: Letrozole — Aromatase inhibitor
  • Drug: Anastrozole — Aromatase inhibitor

Primary Outcomes

  • Invasive breast cancer-free survival (IBCFS) according to the Standardized Definitions for Efficacy End Points (STEEP) criteria in a prospective cohort (Months 36, 48, 60)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-03
Completion: 2032-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2766 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com
Novartis Pharmaceuticals
Interventions
  • Drug: Ribociclib — CDK4/6 inhibitor
  • Drug: Letrozole — Aromatase inhibitor
  • Drug: Anastrozole — Aromatase inhibitor
Study Locations (42 sites)
Novartis Investigative Site, Sochi, Russian Federation 354057 Russia
Novartis Investigative Site, Kaluga, Russia 248007 Russia
Novartis Investigative Site, Pskov, Russia 180000 Russia
Novartis Investigative Site, Ryazan, Russia 390011 Russia
Novartis Investigative Site, Saint Petersburg, Russia 197758 Russia
Novartis Investigative Site, Surgut, Tymen Area 628402 Russia
Novartis Investigative Site, Arkhangelsk, 163045 Russia
Novartis Investigative Site, Barnaul, 656045 Russia
Novartis Investigative Site, Bryansk, 241028 Russia
Novartis Investigative Site, Irkutsk, 664035 Russia
Eligibility Criteria
Inclusion Criteria: Patients from the prospective cohort of the study must meet all of the following criteria: 1. Signed and dated Informed Consent Form (ICF) not later than 28 days after the initiation of adjuvant therapy with ribociclib in combination with aromatase inhibitors (±GnRH agonists). 2. Age ≥18 years at the time of signing the ICF. 3. Histologically verified HR+ HER2-negative stage II-III breast cancer, for which radical treatment was carried out. 4. The adjuvant hormone therapy with aromatase inhibitors (±GnRH agonists) may be started not earlier than 12 months before initiation of therapy with ribociclib. 5. ECOG performance status 0-1 Patients from the retrospective cohort of the study must meet all of the following criteria: 1. Age ≥18 years at the initiation of hormone therapy. 2. Histologically verified HR+ HER2-negative stage II-III breast cancer, for which radical treatment was carried out. 3. Initiation of adjuvant hormone monotherapy with aromatase inhibitors (±GnRH agonists) in the index period from July 1, 2019 to July 1, 2020. 4. Presence of the necessary information in the source documentation. Exclusion Criteria: Patients enrolled in the study in prospective cohort should not meet any of the following criteria. 1. History of therapy with abemaciclib or palbociclib 2. Therapy with ribociclib in combination with AI for more than 28 days at the time of signing the Informed Consent Form 3. Active therapy for other malignant neoplasms 4. Participation in interventional clinical studies at the time of signing the Informed Consent Form Patients enrolled in the study in retrospective cohort should not meet any of the following criteria. 1. Neoadjuvant or adjuvant therapy with CDK4/6 inhibitors 2. A history of another concomitant malignant neoplasm requiring active therapy 3. Participation in interventional clinical studies at the time of treatment for breast cancer 4. Patients experiencing a recurrence during adjuvant hormone therapy can participate if they meet the other inclusion and exclusion criteria.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 240
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is designed to evaluate the effect of using the application on the adherence of patients with luminal HER2- breast cancer (BC) stage II-III to adjuvant therapy with ribociclib in combination with an aromatase inhibitor (AI). The purpose of the app is to increase adherence to treatment by informing patients about the risks of relapse and adverse event prevention and treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Ribociclib — CDK4/6 inhibitor
  • Drug: Letrozole — Aromatase inhibitor
  • Drug: Anastrozole — Aromatase inhibitor

Primary Outcomes

  • Number (%) of patients who remain on treatment with ribociclib + AI over the 12 months period (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-23
Completion: 2029-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com
Novartis Pharmaceuticals
Interventions
  • Drug: Ribociclib — CDK4/6 inhibitor
  • Drug: Letrozole — Aromatase inhibitor
  • Drug: Anastrozole — Aromatase inhibitor
Study Locations (7 sites)
Novartis Investigative Site, Pskov, Russia 180000 Russia
Novartis Investigative Site, Moscow, 115304 Russia
Novartis Investigative Site, Saint Petersburg, 194017 Russia
Novartis Investigative Site, Saint Petersburg, 194291 Russia
Novartis Investigative Site, Saint Petersburg, 197758 Russia
Novartis Investigative Site, Sestroretsk, 197706 Russia
Novartis Investigative Site, Ufa, 450054 Russia
Eligibility Criteria
Inclusion Criteria: 1. Female and male patients with histologically verified and radically treated stage II-III hormone receptor positive HER2-negative breast cancer; 2. Age ≥ 18 at the time of initiation of ribociclib therapy; 3. Patients who were prescribed ribociclib + AI (±GnRH agonist for premenopausal men and women) not earlier than 28 days before signing the informed consent; 4. It is allowed to start adjuvant hormone therapy with AI (±GnRH agonist) not earlier than 12 months before the start of ribociclib; 5. Provision of written informed consent. Exclusion Criteria: 1. Patients participating in any interventional clinical study at the time of signing the informed consent; 2. Patients receiving active treatment for malignant neoplasms other than BC at the time of enrollment.
Conditions Depressive Disorder
Phase Not Applicable
Enrollment 125
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Body awareness plays a crucial role in health and well-being. However, too little research has been carried out on how it manifests in individuals with depressive disorders. The Awareness Body Chart (ABC), a tool developed in recent years to assess body awareness, may provide new insights into the physical experience of people with depression and may lead the way in the application of body-oriented therapies in this cohort. Information about the distribution properties of the Awareness Body Chart in people with depressive disorder will be collected and analysed in this observational study.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Awareness Body Chart Questionnaire (ABC) (Within the first 7 days after admission)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-26
Completion: 2025-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 125 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johannes Kepler University of Linz
Contact Information
Study Contact:
Christian Mittermaier, M.D.
+43 (0)5 7680 83 - 6170
Christian.Mittermaier@kepleruniklinikum.at
Christian Mittermaier, M.D.
+43 (0)5 7680 83 - 6170
Christian.Mittermaier@kepleruniklinikum.at
Kepler University Clinic, Dept. of Physical Medicine & Rehabilitation
Interventions
N/A
Study Locations (1 sites)
Kepler University Clinic, Dept. of Physical Medicine & Rehabilitation, Linz, 4020 Austria
Eligibility Criteria
Inclusion Criteria: * Age 18 - 69 years * Medical diagnosis of a depressive disorder, including depressive adjustment disorder and depressive episodes in the context of bipolar disorder, i.e. one of the following ICD-10 codes: * F32 Depressive Episode * F33 Recurrent Depressive Disorder * F31.3 Bipolar Affective Disorder, current mild or moderate depressive episode * F31.4 Bipolar Affective Disorder, current severe depressive episode without psychotic symptoms * F43.20 Adjustment Disorder with Brief Depressive Reaction * F43.21 Adjustment Disorder with Prolonged Depressive Reaction * Inpatient admission * Written informed consent Exclusion Criteria: * Inability to fill out questionnaires with or without assistance due to language, physical, or cognitive limitations * Acute psychotic state * Known body schema disorders, e.g. due to significant neurological or malignant diseases, eating disorders, congenital or acquired physical limitations such as the absence of a body part * Deafness, blindness
Conditions Cirrhosis, Portal Hypertension Related t...
Phase NA
Enrollment 30
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the efficacy after one month of treatment with Carvedilol (12.5 mg daily) in primary prophylaxis of digestive haemorrhage due to portal hypertension in cirrhosis, by endoscopic ultrasound-guided portal pressure gradient measurement.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Carvedilol — Carvedilol per os, day 1:3.125 mg once, day 2 to day 8: 6.25 mg/day (3.125 mg twice a day), day 9 to day 90 (end of study visit): 12.5 mg/day (6.25 mg twice a day). After the end of the study, treatment with Carvedilol will be prescribed by a cardiologist and continued at the dose of 12.5 mg/day. The follow-up of the patient will be then done according to the standard practice.

Primary Outcomes

  • Percentage of participants with a reduction of at least 10% in the porto-systemic gradient (One month after starting carvedilol.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-16
Completion: 2028-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Clermont-Ferrand
Principal Investigators:
  • Armando Abergel (PRINCIPAL_INVESTIGATOR) - University Hospital, Clermont-Ferrand
Contact Information
Study Contact:
Lise Laclautre
+33473754963
promo_internet_drci@chu-clermontferrand.fr
Armando Abergel
Lise Laclautre
Armando ABERGEL
+33473750523
aabergel@chu-clermontferrand.fr
Chu Estaing Medecine Digestive Et Hepatobiliaire
Interventions
  • Drug: Carvedilol — Carvedilol per os, day 1:3.125 mg once, day 2 to day 8: 6.25 mg/day (3.125 mg twice a day), day 9 to day 90 (end of study visit): 12.5 mg/day (6.25 mg twice a day). After the end of the study, treatment with Carvedilol will be prescribed by a cardiologist and continued at the dose of 12.5 mg/day. The follow-up of the patient will be then done according to the standard practice.
Study Locations (2 sites)
Lise Laclautre, Clermont-Ferrand, 63000 France
Chu Estaing Medecine Digestive Et Hepatobiliaire, Clermont-Ferrand, 63003 France
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years * Suspected portal hypertension associated with cirrhosis (of any aetiology) as defined by: 1. Baveno VII criteria : Liver stiffness ≥ 25 kPa Or Liver stiffness between 20 and 25 kPa and platelets \< 150 G/L Or Liver stiffness between 15 and 20 kPa and platelets \< 110 G/L Or Liver stiffness \> 20 kPa and/or platelets \< 150 G/L in patients with cirrhosis due to NASH Or Oesophageal varices with high risk of bleeding : Size \> 5 mm (stage 2 or 3) Or Size ≤ 5 mm and red spots Or Size ≤ 5 mm and Child-Pugh score C 2. and/or the presence of a radiological sign of portal hypertension : Portosystemic shunts: rectal varices, splenorenal shunts, repermeabilization of the umbilical vein. 3. and/or splenic elasticity \> 50 kPa. * Patients naive to treatment with cardioselective beta blockers * Affiliated to french health insurance system Exclusion Criteria: * Absolute contraindications to beta blockers : * hypersensitivity to the active substance (carvedilol) or to any of the excipients listed in section 6.1 of the summary of product characteristics * patients with severe decompensated heart failure, with signs of fluid overload (oedema, ascites, pulmonary stasis rales), and/or requiring treatment with a positive inotrope or venous vasodilator * second and third-degree atrioventricular blocks (unless presence of a permanent pacemaker) * severe bradycardia (≤ 50 bpm) * cardiac sinus disease (including sino-auricular block) * severe hypotension (systolic pressure \< 85 mm Hg) * cardiogenic shock * severe asthma, severe chronic obstructive pulmonary disease, history of severe bronchospasm * history of anaphylactic reaction * Raynaud's phenomenon * peripheral circulatory disorder: severe obliterative arterial disease of the lower limbs * association with cimetidine * association with class I antiarrhythmics except lidocaine * pulmonary arterial hypertension * Presence of severe acute alcoholic hepatitis (Madrey score ≥ 32). * Current hepatic encephalopathy ≥ Grade 2. * Ongoing hepato-renal syndrome. * Profuse clinical ascites (only if it interferes with the feasibility of echo-endoscopy). * History of oesophageal varices rupture. * Hepatocellular carcinoma active or in remission for less than six months. * Active or resolved portal vein thrombosis for less than six months. * History of digestive surgery that does not allow the porto-systemic gradient to be measured using echo-endoscopy (gastrectomy, by-pass, etc.). * Patients taking antiaggregants (except acetylsalicylic acid) or anticoagulants for embologenic CA/FA. * Severe stage 4 chronic renal insufficiency or stage 5 end-stage renal insufficiency (clearance \< 30 mL/min). * Pregnant or breast-feeding women, or those planning to become pregnant\*. \*A pregnancy test will be carried out for women of childbearing potential, and the investigator will ensure that effective contraception is in place while Carvedilol is being taken and for 5 half-lives after stopping it. * Patients protected by law (under guardianship, curatorship or safeguard of justice) or deprived of their freedom. * Patients currently taking part in another clinical research protocol. * Patients who do not understand French language.

Early Detection of Type 1 Diabetes

NCT06984185
Recruiting
Conditions Type 1 Diabetes
Phase Not Applicable
Enrollment 106
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

T1D is an autoimmune disease characterized by the presence of autoantibodies usually assayed separately on venous blood. The use of a combined test on capillary blood using a blotting paper would facilitate the immunological presymptomatic T1D screening in routine clinical practice as it is easy to perform and can be performed at home by families. However the use of a combined test on blotting paper must be validated before it is used in routine clinical practice for preclinical T1D screening purpose at large scale, starting with pediatric first degree relatives of T1D patients: this is the aim of this study, where we will assess the concordance of 3 autoantibodies rates (anti-GAD65, anti-IA2 and anti-ZnT8) between a combined assay on capillary blotting paper and the individual measurement of these 3 autoantibodies in venous blood at the time of discovery of type 1 diabetes (stage 3). The combined immunological test used in this study has already been validated (test available on the market: (Biosynex - product code: RL 3ZGl/96D); However, it has never been used on capillary blood eluate from blotting paper. The blotting paper to be used is also marketed and used in current clinical practice for newborn screening (test WHATMAN® + SAVER CARDS 903x100 - ref: 034955). Of note: this ELISA 3 screen test does not include IAA. In clinical practice, for stage 3 patients, IAA (from venous samples) is systematically tested for children \< 6-year-old. For older children they are tested only if the other 3 autoantibodies are negative. (IAA are found more commonly in young children and mainly below 4 years old and mark a higher risk of progression at a very young age. A single IAA positivity in children can therefore justify a closer surveillance in the short term). HCL choose to validate the combined assay (3 Screen + blotting paper) in symptomatic children with suspicion of type 1 diabetes at stage 3, to be further used for pre-clinical T1D screening activities across Auvergne Rhone-Alpes region. 3-screen tests have already been used in large screening program (FR1DA). Added to this, any positivity must be confirmed by a second measurement of all 4 individual Aabs on a venous blood sample within 3 months of the positive screening according to the French recommendation. In addition, although it is usual to consider that the attack is targeted in the islets of Langerhans with the destruction of beta cells, the exocrine pancreas is also the site of inflammation, leading to the rapid reduction of the mass of the pancreas, which can impact beta cell function and accelerate the autoimmune process of T1D. With this regard, the level of immunoreactive trypsin on blotting paper could be an early marker of the progression of T1D. The secondary objective of the study is therefore to verify if levels of immunoreactive trypsin on blotting paper, at the time of discovery of type 1 diabetes (stage 3) in pediatric age, is decreased compared to general pediatric…

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: combined assay on capillary blotting paper — combined assay on capillary blotting paper

Primary Outcomes

  • Concordance rate between the autoantibodies combined assay and the individual assays (Day 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-05
Completion: 2027-12-05
Eligibility
Age: 1 Year and older
Sex: ALL
Volunteers: false
Enrollment: 106 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospices Civils de Lyon
Contact Information
Study Contact:
Kevin PERGE, Dr
0472129525
kevin.perge@chu-lyon.fr
Marc NICOLINO, Dr
0472129532
Marc.nicolino@chu-lyon.fr
Kevin Perge, Dr
0472129525
kevin.perge@chu-lyon.fr
Femme Mère Enfant Hospital, Hospices Civils de Lyon
Interventions
  • Diagnostic Test: combined assay on capillary blotting paper — combined assay on capillary blotting paper
Study Locations (1 sites)
Femme Mère Enfant Hospital, Hospices Civils de Lyon, Bron, Rhône 69500 France
Eligibility Criteria
Inclusion criteria: * Children aged over 1 year and under 18 years * BMI \<30.0 kg/m2 * With a diagnosis of stage 3 type 1 diabetes (clinical and laboratory criteria, metabolic acidosis, ketone levels) * Child's consent and no parental opposition Exclusion criteria * Patients with T2D or monogenic diabetes with a known familial history * Patients with cystic fibrosis * History of liver or kidney disease, or pancreatitis * Any progressive disease (other than T2D)
Conditions Obesity, Diabetes Mellitus, Type 2
Phase PHASE1, PHASE2
Enrollment 150
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-ALK7 in adult participants with obesity without Type 2 Diabetes Mellitus (T2DM) (Part 1), and the safety, tolerability, and PD of multiple doses of ARO-ALK7 in adult participants with obesity with and without T2DM, either as monotherapy or in combination with tirzepatide (Part 2).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: ARO-ALK7 — Subcutaneous (SC) injection
  • Drug: Placebo — calculated volume to match active treatment by SC injection

Primary Outcomes

  • Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (Up to Day 253 End of Study (EOS))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-05-09
Completion: 2027-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Arrowhead Pharmaceuticals
Contact Information
Study Contact:
Medical Monitor
626-304-3400
AROALK71001@arrowheadpharma.com
Principle Investigator
Research Site 8
Principle Investigator
Research Site 7
Interventions
  • Drug: ARO-ALK7 — Subcutaneous (SC) injection
  • Drug: Placebo — calculated volume to match active treatment by SC injection
Study Locations (8 sites)
Research Site 8, Morayfield, QLC 4506 Australia
Research Site 7, Nedlands, Western Australia 6009 Australia
Research Site 5, Grafton, Auckland 1010 New Zealand
Research Site 6, Papatoetoe, Auckland 2025 New Zealand
Research Site 3, Takapuna, Auckland 0622 New Zealand
Research Site 1, Auckland, 1010 New Zealand
Research Site 2, Christchurch, 8011 New Zealand
Research Site 4, Rotorua, 3010 New Zealand
Eligibility Criteria
Inclusion Criteria: * Obesity, defined as body mass index (BMI) between 30-50 kilograms (kg)/square meter (m\^2), inclusive, with weight at Screening not to exceed 159 kg (350 pounds \[lbs\]) * At least one self-reported, unsuccessful attempt at weight loss with lifestyle modification * No abnormal finding of clinical relevance at Screening that could adversely impact participant safety during the study or adversely impact study results * Female participants of childbearing potential must agree to use highly effective contraception and male participants with female partners of childbearing potential must agree to use a condom during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later. Participants must not donate sperm or eggs during the study for at least 90 days following the end of the study or last dose of study drug, whichever is later Exclusion Criteria: * Self-reported (or documented) weight gain or loss \>5% within 3 months prior to Screening * Use of glucagon-like peptide-1 receptor agonist (GLP-1RAs) (liraglutide, semaglutide, etc.) for any indication within 6 months prior to Screening * Use of non-GLP-1R medications for weight loss within 3 months prior to Screening, including but not limited to naltrexone/bupropion, orlistat, phentermine/topiramate, and other prescription or over-the-counter medication or supplement taken for weight loss purposes * Obesity attributable primarily in the Investigator's opinion to medication use, monogenic or endocrinologic disorders (other than polycystic ovary syndrome) * History of prior surgical or device-based therapy for obesity (including endoscopic bariatric procedures) * Use of medications or therapies strongly associated with weight gain, alterations in body composition, or increase in muscle mass, within 3 months prior to Screening * Type 1 diabetes mellitus Note: Additional inclusion/exclusion criteria may apply per protocol.
Conditions Breast Cancer
Phase PHASE2
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical research study is to learn about the effects of giving radiotherapy alone after lumpectomy to patients who have early-stage, low-risk breast cancers and who are 60 years of age or older.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Adjuvant Radiotherapy — Participants will receive treatment following Lumpectomy

Primary Outcomes

  • Safety and Adverse Events (AEs) (Through study completion; an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-17
Completion: 2030-12-31
Eligibility
Age: 60 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Simona Shatelman, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Simona Shaitelman, MD
(713) 563-8491
sfshaitelman@mdanderson.org
Simona Shaitelman, MD
713-563-8491
sfshaitelman@mdanderson.org
The University of Texas M. D. Anderson Cancer Center
Simona Shaitelman, MD
The University of Texas M. D. Anderson Cancer Center
Interventions
  • Radiation: Adjuvant Radiotherapy — Participants will receive treatment following Lumpectomy
Study Locations (1 sites)
The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of pathologically-confirmed invasive breast cancer 2. Age ≥ 60 years 3. Treatment with breast conserving surgery 4. Pathologic T stage of T1 or T2 with total tumor size ≤ 3cm including any component of DCIS that may exist in conjunction with invasive disease 5. Ki-67 . 20% and/or Oncotype 0-10 (Ultra Low) 6. Final surgical margins negative, defined as no tumor on ink. Lobular carcinoma in situ involving the final surgical margin will be disregarded. 7. Tumor must be estrogen receptor positive, progesterone receptor positive and HER2Neu non-amplified as per current College of American Pathologists guidelines 8. Clinical nodal stage cN0 9. If pathologic nodal staging is obtained, then pN0 or pN0(i+) 10. Patients have had or have a scheduled discussion with a breast medical oncologist regarding adjuvant treatment options 11. Patients who have met criteria 4.1.1-4.1.9 who never initiate endocrine therapy OR who initiate adjuvant endocrine therapy but discontinue it within 6 months of initiation \* In some clinical scenarios, patients may have a particularly small volume of tumor, making it not be feasible for all of these biomarkers to be evaluated. In this scenario, if the PI and/or Protocol Collaborators are able to document that a patient is being treated as if they have luminal A (biologically favorable) breast cancer then the patient is eligible for enrollment if all other eligibility criteria are met. Exclusion Criteria: 1. Node positive disease (N1-3) 2. Metastatic disease (M1) 3. Grade 3 disease and lymphovascular space invasion in the tumor 4. Synchronous bilateral breast cancer 5. Receipt of neoadjuvant therapy 6. Diagnosis of a collagen vascular disease associated with an increased incidence of radiation toxicities such as scleroderma or systemic lupus erythematosis 7. Diagnosis of other cancer within the prior 5 years, excluding basal or squamous cell carcinoma of the skin that has been treated 8. Patient with psychiatric illness/social situations that would limit compliance with study requirements 9. Prior radiotherapy to the index breast or recurrent cancer of the breast 10. Known carrier of a mutation associated with predisposition to breast cancer development, including BRCA1 or BRCA2